

28 August 2017

The Manager Company Announcements Office ASX Limited Level 6, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

LifeHealthcare Group Limited (ACN 166 525 186) (ASX:LHC) Notice under section 708A(5)(e) of the Corporations Act

This notice is given by LifeHealthcare Group Limited (ACN 166 525 186) (ASX:LHC) (the Company) under section 708(5)(e) of the Corporations Act 2011 (Cth) (the Corporations Act).

The Company advises that:

- a) the Company has on the 24th of August 2017 issued 58,179 fully paid ordinary shares and on the 25th of August 2017 issued 418,889 fully paid ordinary shares (the New Shares) to satisfy the exercise of options granted to eligible employees of the Company under the terms of the Company's Long Term Incentive Plan;
- b) the Company issued the New Shares without disclosure under Part 6D.2 of the Corporations Act;
- c) as at the date of this notice, the Company has complied with:
 - I. the provisions of Chapter 2M of the Corporations Act as they relate to the Company; and
 - II. section 674 of the Corporations Act; and
- d) as at the date of this notice, there is no "excluded information" which is required to be set out in this notice pursuant to section 708A(6)(e) or section 708AA(7)(d) of the Corporations Act.

Yours sincerely,

Dean Taylor

Company Secretary

LifeHealthcare Group Limited

> Not your typical multinational

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$

ABN					
72 166	5 525 186				
We (t	We (the entity) give ASX the following information.				
	t 1 - All issues ust complete the relevant sections (attac	th sheets if there is not enough space).			
1	*Class of *securities issued or to be issued	Ordinary shares			
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	477,068			
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid Ordinary Shares			

04/03/2013

Name of entity

LifeHealthcare Group Limited

⁺ See chapter 19 for defined terms.

Do the *securities rank equally 4 in all respects from the +issue date with an existing +class of quoted +securities?

Yes, will rank equally in all respects with existing Ordinary Shares of the Company from the date of issues.

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust. distribution) interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

\$736,068.21

Issue price or consideration 5

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Exercise of vested Unlisted options issued under the Company's Long Term Incentive Plan.

Is the entity an +eligible entity ба that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the

6b The date the security holder N/A resolution under rule 7.1A was passed

comply with section 6i

subject of this Appendix 3B, and

No.

Number of *securities issued 6с without security holder approval under rule 7.1

477,068 fully paid ordinary shares.

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6е	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	1 1111	ares (Exception 4 – an on conversion of).
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	24 August 2017 and 25	August 2017
	ï		
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 44,596,191 Ordinary Shares	†Class Ordinary Shares

04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and ⁺class of all ⁺securities not quoted on ASX (including the ⁺securities in section 2 if applicable)

Number	+Class
2,447,344	Options and
Options	Performance
117,679	Rights
Performance Rights	_
(Note: The balance of Options and Performance Rights is affected by and may be varied by a number of events including the lapse of Options and Performance Rights in accordance with the Long Term Incentive Plan	
Incentive Plan rules).	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Pro rata issue

Is security holder approval N/A

	required?	
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	+Record date to determine	N/Δ

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

N/A

entitlements

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

17	Policy for deciding entitlements	N/A
	in relation to fractions	
-0	Names of assentation in which the	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A

04/03/2013

⁺ See chapter 19 for defined terms.

		
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A
	t 3 - Quotation of sec ed only complete this section if you are ap Type of *securities (tick one) *Securities described in Part	oplying for quotation of securities
(b)		nd of the escrowed period, partly paid securities that become fully paid,
	employee incentive snare securities whe securities	n restriction ends, securities issued on expiry or conversion of convertible
Entit	ies that have ticked box 3	4(a)
Addi	ional securities forming a new	class of securities
Tick to locum	indicate you are providing the informatients	ion or
35		securities, the names of the 20 largest holders of the he number and percentage of additional ⁺ securities
36	If the *securities are *equity	securities, a distribution schedule of the additional

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

	+securities setting out the no 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	umber of holders in the ca	tegories
37	A copy of any trust deed for	the additional ⁺ securities	
Entit	ties that have ticked box 3	34(b)	
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class

04/03/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4	We give ASX the information and documents required by this form. If an
	information or document is not available now, we will give it to ASX befor
	†quotation of the †securities begins. We acknowledge that ASX is relying or
	the information and documents. We warrant that they are (will be) true and
	complete.

Sign here:

(Director/Company secretary)

Date: 28/8/17

Print name:

DEAN TAYLOR

04/03/2013

⁺ See chapter 19 for defined terms.